INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Multivalent vaccine formulation with BmVAL-1 and BmALT-2 confer significant protection against challenge infections with Brugia malayi in mice and jirds

Show full item record

Bookmark or cite this item: http://hdl.handle.net/10027/7785

Files in this item

File Description Format
PDF RRTM-13679-mult ... -bmalt-2-con_032311(2).pdf (385KB) (no description provided) PDF
Title: Multivalent vaccine formulation with BmVAL-1 and BmALT-2 confer significant protection against challenge infections with Brugia malayi in mice and jirds
Alternative Title: Multivalent vaccine for lymphatic filariasis
Author(s): Kalyanansundaram, Ramaswamy; Balumuri, Padmavathi
Subject(s): Brugia malayi BmALT-2 BmVAL-1 lymphatic filariasis
Abstract: Purpose: Lymphatic filariasis, a mosquito-borne infection, affects 120 million people in 83 different countries. Mass drug administration is fully underway in several parts of the world to eradicate this infection by year 2020. Drugs alone are highly efficient treatments, but long-term sustainable prophylaxis requires an effective vaccine. No vaccines are available for humans and animals despite several potential candidate vaccine antigens having been identified. Brugia malayi vespid venom allergen homolog-like protein (BmVAL-1) and B. malayi abundant larval transcript (BmALT-2) are two of the most promising vaccine candidates. We evaluated various vaccination regimens consisting of DNA and protein antigens and evaluated the potential of monovalent and multivalent vaccine formulations in mice and jird animal models. Methods: Mice and jirds were vaccinated with monovalent DNA preparations of BmVAL-1 or BmALT-2 in pVAX-1 vector or monovalent protein preparations of rBmVAL-1 and rBmALT-2 in alum using a homologous or heterologous prime boost approach. These vaccine regimens were then compared with a multivalent vaccine formulation consisting of DNA or hybrid protein formulation of the two antigens. Challenge experiments were performed with B. malayi L3 in mice and jirds to evaluate the degree of protection, and immunological parameters were determined in mice and humans to elucidate the characteristics of the protective immune responses. Results: Vaccination with monovalent BmVAL-1 vaccine conferred 39% (DNA vaccine) to 54% (DNA prime and protein boost) protection in mice. A similar degree of protection was observed in jirds (50% to 52%). Monovalent BmALT-2 afforded 51% to 75% protection in mice and 58% to 79% protection in jirds. Our testing of a multivalent formulation of BmVAL-1 and BmALT-2, showed 57% to 82% protection in mice and 77% to 85% protection in jirds. A heterologous prime boost approach using the multivalent vaccine gave the highest degree of protection in both mice and jirds. Serological analysis in mice showed that BmVAL-1 vaccination induced an IgG1, IgG2a, and IgG3 antibody response, whereas BmALT-2 vaccination predominantly induced an IgG1 and IgG3 antibody response. Cytokine responses of antigen-responding cells in the spleen secreted predominantly IFN-γ and IL-5 in response to BmVAL-1, and IL-4, and IL-5 in response to BmALT-2. Conclusion: A multivalent vaccine formulation of BmVAL-1 and BmALT-2 given as a prime boost regimen gave significant protection against lymphatic filariasis caused by B. malayi in mice and jirds. Because putatively immune endemic normal subjects also carry protective antibodies against BmVAL-1 and BmALT-2, developing this multivalent formulation as a prophylactic vaccine against B. malayi for human and veterinary use has great potential.
Issue Date: 2011-03-24
Publisher: Dove Medical Press
Citation Info: Kalyanansundaram, Ramaswamy, Balumuri, Padmavathi 2011. Multivalent vaccine formulation with BmVAL-1 and BmALT-2 confer significant protection against challenge infections with Brugia malayi in mice and jirds. Research and Reports in Tropical Medicine, 2:1:45-46. DOI: 10.2147/RRTMS13679
Type: Article
Description: The original version of this article is available through Dove Medical Press, Research and Reports in Tropical Medicine at www.dovepress.com; DOI: 10.2147/RRTMS13679.
URI: http://hdl.handle.net/10027/7785
ISSN: 1179-7282
Sponsor: This study was supported by NIH grant (AI06474). B. malayi L3s were obtained from the NIAID/NIH Filariasis Research Reagent Resource Center (FR3) at the University of Georgia, Athens, GA.
Date Available in INDIGO: 2011-05-27
 

This item appears in the following Collection(s)

Show full item record

Statistics

Country Code Views
United States of America 101
China 25
United Kingdom 7
Denmark 1
Netherlands 1

Browse

My Account

Information

Access Key